Key facts
- Canid’s last known valuation is $54.0M.
- It has raised $16.4M; the latest was Early Stage VC ($13.4M) in Oct 2024.
- Notable investors include Alumni Ventures, FJ Labs, Pareto Holdings, I2BF Global Ventures, Brooklyn Bridge Ventures — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Canid
- ·The full record, as it builds
Funding rounds
No funding rounds for Canid are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Canid
Developer of a healthcare dashboard and process tool intended to simplify vaccination record management. The company's tool offers administrative consulting, secures vaccine margins, automates your vaccine workflow, and oversees vaccine inventory, enabling state officials and pediatric practitioners to focus on their day-to-day practice.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 47
- Website
- canid.io/
- Ownership
- Privately Held (backing)
Canid doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Canid shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Canid in its N-PORT filings yet. We sweep new filings monthly.